New Jersey's The Medicines Co. has tied the knot with Tokyo's SymBio, a deal that gives the Japanese company the exclusive license to develop and commercialize The Medicine Co.'s IONSYS transdermal pain system in its home country.
Partners Merck and Incyte are broadening their oncology alliance, moving into Phase III with a pair of treatments that use the body's natural defenses to fight cancer.
3M announced that it is helping Impel Neuoropharma develop its Precision Olfactory Delivery for delivery of neurological drugs into the brain and nervous system. The companies said the alliance leverages 3M's experience in the inhaled and nasal drug delivery arenas, in an otherwise vague release that lacked details about the nature of the partnership.
Roche won a contract in the Netherlands to provide its HPV test for primary screening of cervical cancer through the country's national cervical cancer screening program, a milestone for the company more than a year after its scored FDA approval for its diagnostic for frontline HPV testing.
Eli Lilly has expanded its R&D partnership with China's Innovent Biologics, bringing in three potential immunotherapies for cancer and adding another $1 billion in potential value to the existing alliance.
Japan's Astellas Pharma has splashed out $300 million to U.S.-based Immunomic Therapeutics for its LAMP-vax platform to treat or prevent allergic diseases, gaining exclusive global development and commercialization rights, according to a press release.
China's Innovent Biologics has deepened a pact with Eli Lilly by including immuno-oncology bispecific antibodies for Innovent in Greater China and for the Indianapolis-based firm outside of the country, setting a new benchmark in a white-hot area of collaboration deals.
China biotech 3SBio said it has signed an exclusive licensing deal with South Korea's Alteogen for the development, manufacturing and marketing of ALT-P7, an antibody-drug conjugate used in cancer treatments, keeping it on a steady deal streak since a public relisting this summer.
Onkos Surgical has secured a Series A financing and partnered with MicroPort Orthopedics. The financial details were undisclosed in the company's announcement, but an SEC filing reveals that Onkos recently secured the first $6.1 million of a financing that's expected to total $15.3 million.
The Internet of Things revolution for medical devices is here. And, not too surprisingly, it's being led by Amazon--yet another big-name tech contender working to get in on the evolution of healthcare via technology. Google, along with other big IT names such as IBM, Salesforce and Siemens, are all in the midst of trying to secure a profitable spot in next-gen healthcare.